ABSTRACT
Ischemic colitis shock-associated still is a not well-defined clinical entity. The authors describe symptoms, clinical course and treatment in a case recently observed. They outline the difficulties of preoperative diagnosis and the need of a not postponable surgical treatment due to shock and peritonitis.
Subject(s)
Colitis, Ischemic/pathology , Adenocarcinoma/pathology , Aged , Colectomy , Colitis, Ischemic/surgery , Colon/pathology , Humans , Male , Necrosis , Rectal Neoplasms/pathology , Reoperation , Shock/pathology , Shock/surgeryABSTRACT
Twenty-nine advanced breast cancer patients, considered unable to tolerate conventional cytotoxic chemotherapy, were treated with a weekly schedule of epirubicin (15 mg/m2 i.v.). All patients were fully evaluable. A remission of 34.5% was observed (2 CR; 8 PR), with a median duration of response of 9 months (range, 3-24 months). Side effects were mild, and on the whole the toxicity was negligible. This regimen showed a favorable therapeutic ratio in our series and seems active and well tolerated even in elderly and/or poor performance status patients.
